EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy

Leire Pedrosa iD, Carmen Bedia iD, Diouldé Diao iD, Alejandra Mosteiro, Abel Ferrés iD, Elisabetta Stanzani iD, Fina Martínez-Soler iD, Avelina Tortosa iD, Estela Pineda iD, Iban Aldecoa iD, Marc Centellas, Marta Muñoz-Tudurí iD und 3 weitere

Cells · 2023

DOI: 10.3390/cells12081125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Leire Pedrosa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Oncological Neurosurgery, Neurosurgery Service, Hospital Clinic de Barcelona-FCRB, 08036 Barcelona, Spain. Hauptthemen laut MEDLINE: Glioblastoma, Photochemotherapy, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Laboratorios Gebro Pharma S.A, Spanish Ministry of Health and Consumer Affairs, the ISCIII-Subdirección General de Evaluación, AECC (Spanish Association Against Cancer, Fondo Europeo de Desarrollo Regional (FEDER).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The high recurrence of glioblastoma (GB) that occurs adjacent to the resection cavity within two years of diagnosis urges an improvement of therapies oriented to GB local control. Photodynamic therapy (PDT) has been proposed to cleanse infiltrating tumor cells from parenchyma to ameliorate short long-term progression-free survival. We examined 5-aminolevulinic acid (5-ALA)-mediated PDT effects as therapeutical treatment and determined optimal conditions for PDT efficacy without causing phototoxic injury to the normal brain tissue.

Methods

We used a platform of Glioma Initiation Cells (GICs) infiltrating cerebral organoids with two different glioblastoma cells, GIC7 and PG88. We measured GICs-5-ALA uptake and PDT/5-ALA activity in dose-response curves and the efficacy of the treatment by measuring proliferative activity and apoptosis.

Results

5-ALA (50 and 100 µg/mL) was applied, and the release of protoporphyrin IX (PpIX) fluorescence measures demonstrated that the emission of PpIX increases progressively until its stabilization at 24 h. Moreover, decreased proliferation and increased apoptosis corroborated the effect of 5-ALA/PDT on cancer cells without altering normal cells.

Conclusions

We provide evidence about the effectiveness of PDT to treat high proliferative GB cells in a complex in vitro system, which combines normal and cancer cells and is a useful tool to standardize new strategic therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPhotochemotherapyBrain NeoplasmsGliomaHumansPhotosensitizing AgentsCoculture TechniquesCell Line, TumorAminolevulinic AcidBrainOrganoids

Stichwörter der Autor:innen

3D tumor models5-ALAdrug screeningglioblastomaneurological cancersorganoidspersonalized medicinephotodynamic therapyspheroids

Substanzen

Photosensitizing AgentsAminolevulinic Acid

Autor:innen und Institutionen

  • Laboratory of Experimental Oncological Neurosurgery, Neurosurgery Service, Hospital Clinic de Barcelona-FCRB, 08036 Barcelona, Spain.
  • Institute of Environmental Assessment and Water Research (IDAEA-CSIC), 08034 Barcelona, Spain.
  • Department of Neurosurgery, Hospital Clínic de Barcelona, University of Barcelona, 08036 Barcelona, Spain.
  • Laboratory of Pharmacology and Brain Pathology, IRCCS Humanitas Research Hospital, 20089 Milan, Italy.
  • Apoptosis and Cancer Unit, Department of Basic Nursing, IDIBELL, Faculty of Medicine and Health Sciences, University of Barcelona, 08907 L'Hospitalet del Llobregat, Spain.
  • Medical Oncology Department, Hospital Clinic and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain.

ORCID-Profile: Leire Pedrosa, Carmen Bedia, Diouldé Diao, Abel Ferrés, Elisabetta Stanzani, Fina Martínez-Soler, Avelina Tortosa, Estela Pineda, Iban Aldecoa, Marta Muñoz-Tudurí, Ana Sevilla, Àngels Sierra

Förderung

  • Laboratorios Gebro Pharma S.A
  • Spanish Ministry of Health and Consumer Affairs, the ISCIII-Subdirección General de Evaluación, AECC (Spanish Association Against Cancer
  • Fondo Europeo de Desarrollo Regional (FEDER)
  • MCIN/AEI/10.13039/501100011033
  • European Union Next GenerationEU/PRTR and the Merck Salud Foundation
  • “ESF investing in your future”

Zitieren

APA

Pedrosa, L., Bedia, C., Diao, D., Mosteiro, A., Ferrés, A., Stanzani, E., Martínez-Soler, F., Tortosa, A., Pineda, E., Aldecoa, I., Centellas, M., Muñoz-Tudurí, M., Sevilla, A., Sierra, À., & González Sánchez, J. J. (2023). Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy. Cells. https://doi.org/10.3390/cells12081125

Vancouver

Pedrosa L, Bedia C, Diao D, Mosteiro A, Ferrés A, Stanzani E, et al. Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy. Cells. 2023. doi:10.3390/cells12081125

BibTeX
@article{Pedrosa2023,
  author = {Pedrosa, Leire and Bedia, Carmen and Diao, Diouldé and Mosteiro, Alejandra and Ferrés, Abel and Stanzani, Elisabetta and Martínez-Soler, Fina and Tortosa, Avelina and Pineda, Estela and Aldecoa, Iban and Centellas, Marc and Muñoz-Tudurí, Marta and Sevilla, Ana and Sierra, Àngels and González Sánchez, José Juan},
  title = {Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12081125}
}
Kostenlos starten →